LBA60 Phase III study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA)

Authors:
  • ZPZ. Peng
    Z. Peng
  • JWJ. Wang
    J. Wang
  • YZY. Zhang
    Y. Zhang
  • HLH. Li
    H. Li
  • QZQ. Zhao
    Q. Zhao
  • XZX. Zhu
    X. Zhu
  • SWS. Wei
    S. Wei
  • YCY. Cheng
    Y. Cheng
  • WYW. Yang
    W. Yang
  • JYJ. Yao
    J. Yao
  • MZM. Zhang
    M. Zhang
  • LXL. Xie
    L. Xie

Abstract
No abstract available